So real questions moving forward in the near term: <br /> <br /> -Where are the generics at in determining bio-equivalence to Vascepa with the FDA? <br /> -Can a settlement with generics be reached per settlement terms with Teva? <br /> -Will AMRN give us some more info or throw us a bone with unaudited Q1 results? <br /> -If the generic launches, will Europe honor Teva's exclusivity rights, thus voiding the 10 year exclusivity? <br /> <br /> If someone has access to the full settlement agreement with Teva please post it. If it wasn't for this unknown, I would dump every penny I had in this.